Myocardial Infarction - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 357
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MD027BAF1AAEN
Leaflet:

Download PDF Leaflet

Myocardial Infarction - Pipeline Review, H2 2016
Myocardial Infarction - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H2 2016’, provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
  • The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
  • The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myocardial Infarction
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Myocardial Infarction Overview
Therapeutics Development
Myocardial Infarction - Therapeutics under Development by Companies
Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes
Myocardial Infarction - Pipeline Products Glance
Myocardial Infarction - Products under Development by Companies
Myocardial Infarction - Products under Investigation by Universities/Institutes
Myocardial Infarction - Companies Involved in Therapeutics Development
Myocardial Infarction - Therapeutics Assessment
Drug Profiles
Myocardial Infarction - Dormant Projects
Myocardial Infarction - Discontinued Products
Myocardial Infarction - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Myocardial Infarction, H2 2016
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Development by Companies, H2 2016 (Contd.3)
Number of Products under Development by Companies, H2 2016 (Contd.4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Development by Companies, H2 2016 (Contd.4)
Products under Development by Companies, H2 2016 (Contd.5)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd.1)
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Myocardial Infarction - Pipeline by Asterias Biotherapeutics, Inc., H2 2016
Myocardial Infarction - Pipeline by AstraZeneca Plc, H2 2016
Myocardial Infarction - Pipeline by Athersys, Inc., H2 2016
Myocardial Infarction - Pipeline by Bayer AG, H2 2016
Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H2 2016
Myocardial Infarction - Pipeline by BioCardia, Inc., H2 2016
Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016
Myocardial Infarction - Pipeline by Capricor Therapeutics, Inc., H2 2016
Myocardial Infarction - Pipeline by CellProthera, H2 2016
Myocardial Infarction - Pipeline by Celyad SA, H2 2016
Myocardial Infarction - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016
Myocardial Infarction - Pipeline by Compugen Ltd., H2 2016
Myocardial Infarction - Pipeline by CSL Limited, H2 2016
Myocardial Infarction - Pipeline by Cynata Therapeutics Limited, H2 2016
Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
Myocardial Infarction - Pipeline by FibroGen, Inc., H2 2016
Myocardial Infarction - Pipeline by Hemostemix Ltd, H2 2016
Myocardial Infarction - Pipeline by Hope Pharmaceuticals, Inc., H2 2016
Myocardial Infarction - Pipeline by Human Stem Cells Institute, H2 2016
Myocardial Infarction - Pipeline by HUYA Bioscience International, LLC, H2 2016
Myocardial Infarction - Pipeline by Inotrem S.A., H2 2016
Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H2 2016
Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Myocardial Infarction - Pipeline by LegoChem Biosciences, Inc, H2 2016
Myocardial Infarction - Pipeline by LG Life Science LTD., H2 2016
Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H2 2016
Myocardial Infarction - Pipeline by Mesoblast Limited, H2 2016
Myocardial Infarction - Pipeline by miRagen Therapeutics, Inc., H2 2016
Myocardial Infarction - Pipeline by Moderna Therapeutics Inc, H2 2016
Myocardial Infarction - Pipeline by Navya Biologicals Pvt Ltd, H2 2016
Myocardial Infarction - Pipeline by NeuroVive Pharmaceutical AB, H2 2016
Myocardial Infarction - Pipeline by New World Laboratories, Inc., H2 2016
Myocardial Infarction - Pipeline by Novartis AG, H2 2016
Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H2 2016
Myocardial Infarction - Pipeline by Omeros Corporation, H2 2016
Myocardial Infarction - Pipeline by Opsona Therapeutics Limited, H2 2016
Myocardial Infarction - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Myocardial Infarction - Pipeline by Pfizer Inc., H2 2016
Myocardial Infarction - Pipeline by Pharmathen Pharmaceuticals S.A., H2 2016
Myocardial Infarction - Pipeline by Primary Peptides, Inc., H2 2016
Myocardial Infarction - Pipeline by Quantum Genomics SA, H2 2016
Myocardial Infarction - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
Myocardial Infarction - Pipeline by Recardio GmbH, H2 2016
Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
Myocardial Infarction - Pipeline by Serodus ASA, H2 2016
Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016
Myocardial Infarction - Pipeline by Stealth BioTherapeutics Inc., H2 2016
Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016
Myocardial Infarction - Pipeline by Targazyme, Inc., H2 2016
Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
Myocardial Infarction - Pipeline by TiGenix NV, H2 2016
Myocardial Infarction - Pipeline by Vicore Pharma AB, H2 2016
Myocardial Infarction - Pipeline by XBiotech Inc, H2 2016
Myocardial Infarction - Pipeline by Yuyu Pharma, Inc., H2 2016
Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Myocardial Infarction - Dormant Projects, H2 2016
Myocardial Infarction - Dormant Projects (Contd.1), H2 2016
Myocardial Infarction - Dormant Projects (Contd.2), H2 2016
Myocardial Infarction - Dormant Projects (Contd.3), H2 2016
Myocardial Infarction - Dormant Projects (Contd.4), H2 2016
Myocardial Infarction - Dormant Projects (Contd.5), H2 2016
Myocardial Infarction - Dormant Projects (Contd.6), H2 2016
Myocardial Infarction - Dormant Projects (Contd.7), H2 2016
Myocardial Infarction - Dormant Projects (Contd.8), H2 2016
Myocardial Infarction - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Myocardial Infarction, H2 2016
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Amarantus Bioscience Holdings, Inc.
Asterias Biotherapeutics, Inc.
AstraZeneca Plc
Athersys, Inc.
Bayer AG
Bharat Biotech International Limited
BioCardia, Inc.
Biscayne Pharmaceuticals, Inc.
Capricor Therapeutics, Inc.
CellProthera
Celyad SA
Chrysalis BioTherapeutics, Inc.
Compugen Ltd.
CSL Limited
Cynata Therapeutics Limited
Diffusion Pharmaceuticals Inc.
FibroGen, Inc.
Hemostemix Ltd
Hope Pharmaceuticals, Inc.
Human Stem Cells Institute
HUYA Bioscience International, LLC
Inotrem S.A.
Juventas Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Lee's Pharmaceutical Holdings Limited
LegoChem Biosciences, Inc
LG Life Science LTD.
Medestea Research & Production S.p.A.
Mesoblast Limited
miRagen Therapeutics, Inc.
Moderna Therapeutics Inc
Navya Biologicals Pvt Ltd
NeuroVive Pharmaceutical AB
New World Laboratories, Inc.
Novartis AG
NuvOx Pharma LLC
Omeros Corporation
Opsona Therapeutics Limited
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Pharmathen Pharmaceuticals S.A.
Primary Peptides, Inc.
Quantum Genomics SA
Quark Pharmaceuticals, Inc.
Recardio GmbH
RegeneRx Biopharmaceuticals, Inc.
Serodus ASA
Silver Creek Pharmaceuticals, Inc.
Stealth BioTherapeutics Inc.
Stemedica Cell Technologies, Inc.
TaiGen Biotechnology Co., Ltd.
Targazyme, Inc.
The International Biotechnology Center (IBC) Generium
TiGenix NV
Vicore Pharma AB
XBiotech Inc
Yuyu Pharma, Inc.
Zydus Cadila Healthcare Limited
Skip to top


Myocardial Ischemia - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 84 pages
Post - Myocardial Infarction - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Myocardial Fibrosis - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 77 pages
Myocardial Fibrosis - Pipeline Review, H1 2016 US$ 2,000.00 Jun, 2016 · 82 pages

Ask Your Question

Myocardial Infarction - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: